Methenamine Hippurate: A Forgotten but Powerful Ally in Preventing Recurrent Urinary Tract Infections

Introduction

For many people—especially women, older adults, and those with chronic health conditions—recurrent urinary tract infections (UTIs) can feel like an endless cycle. Antibiotics may clear the infection temporarily, but the relief is often short-lived. Over time, repeated antibiotic exposure can lead to resistance, side effects, and a disrupted gut and vaginal microbiome.

Fortunately, there’s a time-tested, non-antibiotic option that’s making a comeback in preventive urology and infectious disease practice: Methenamine Hippurate (brand name Hiprex). Although first introduced in the 1890s, it’s proving to be one of the most effective and sustainable tools for UTI prophylaxis, particularly in women with recurrent infections.

How Methenamine Hippurate Works

Unlike antibiotics that directly kill bacteria, methenamine works through a clever chemical mechanism. Once it reaches the bladder, it releases formaldehyde—a potent antiseptic—but only when the urine is acidic (pH < 6).

Here’s the process simplified:

1. Methenamine is absorbed in the gut and excreted unchanged into the urine.
2. In acidic urine, methenamine breaks down into formaldehyde and ammonia.
3. Formaldehyde acts as a broad-spectrum bactericidal agent, killing bacteria regardless of resistance patterns.
4. Because formaldehyde is not an antibiotic, bacteria cannot develop resistance to it.

This mechanism makes methenamine uniquely suited for long-term prevention, particularly in those for whom repeated antibiotic exposure is undesirable or unsafe.

Who Benefits Most from Methenamine Prophylaxis?

Clinical studies and guidelines suggest methenamine is especially useful for:

• Women with recurrent uncomplicated UTIs (≥2 infections in 6 months or ≥3 in a year).
• Postmenopausal women, especially those already using topical vaginal estrogen.
• Patients with neurogenic bladder or intermittent catheterization where sterile urine is difficult to maintain.
• Older adults or renal transplant recipients for whom antibiotics carry significant risks.
• Patients on chronic antibiotic prophylaxis who wish to transition to a non-antibiotic alternative.

A recent randomized controlled trial (the ALTAR study), found methenamine hippurate to be non-inferior to daily low-dose antibiotics for UTI prevention—without contributing to antibiotic resistance.

The Key to Success: Keeping the Urine Acidic

Methenamine only converts to its active form, formaldehyde, when the urine is acidic (pH < 6).
If the urine becomes alkaline (pH ≥ 6), the drug remains inactive and loses its antibacterial effect.

Ways to Help Acidify Urine:

1. Ascorbic acid (Vitamin C):
   • Commonly taken at 500–2000 mg daily, divided into two doses.
   • Helps maintain acidic urine and adds antioxidant benefits.
2. Cranberry extract or unsweetened cranberry juice:
   • Contains organic acids that slightly lower urine pH.
   • Also reduces bacterial adherence to bladder walls.
3. Protein-rich diet:
   • Animal protein (meat, fish, poultry, eggs) produces acidic metabolites.
   • A moderate increase can naturally support a lower urinary pH.
4. Avoid urine alkalinizers:
   • Sodium bicarbonate, potassium citrate, acetazolamide, and certain antacids can make urine alkaline and render methenamine ineffective.
5. Monitor your pH:
   • Over-the-counter urine pH test strips allow for easy home monitoring.
   • Aim for a pH between 5.0 and 6.0 for optimal effectiveness.

Typical Dosing and Administration

• Methenamine hippurate: 1 gram twice daily (morning and evening), with or after meals.
• Adequate hydration is important, but excessive fluid intake that significantly dilutes urine may lower the concentration of formaldehyde.

The medication is generally well-tolerated. Mild stomach upset can occur but is often alleviated by taking it with food.

Important Safety Considerations

1. Avoid in severe renal or hepatic impairment: The drug’s metabolism and clearance depend on normal kidney and liver function.
2. Not for active UTIs: Methenamine prevents infections but does not treat active ones. Active infections require antibiotics before starting prophylaxis.
3. Avoid concurrent alkalinizing agents: These interfere with formaldehyde formation.
4. Possible interactions: Use caution with sulfonamides (e.g., sulfamethoxazole) — formaldehyde may react to form insoluble precipitates.
5. Pregnancy and lactation: Generally considered safe, but always confirm with your prescriber.

Combining Methenamine with Other Preventive Strategies

A holistic approach yields the best results. Many urologists and infectious disease specialists combine methenamine prophylaxis with:

• Topical vaginal estrogen for postmenopausal women to restore mucosal health.
• Probiotics (Lactobacillus species) to maintain a healthy vaginal microbiome.
• Hydration optimization — enough fluids to prevent stasis, but not excessive.
• Behavioral strategies: regular voiding, post-coital urination, avoiding irritants (perfumed soaps, douches, etc.).

Evidence Snapshot

• ALTAR Trial (BMJ 2022):
  Methenamine hippurate was as effective as low-dose antibiotics in preventing recurrent UTIs over 12 months, with fewer adverse events and less antimicrobial resistance.
• Systematic Reviews:
  Meta-analyses show methenamine significantly reduces UTI recurrence compared with placebo, especially in women without structural urinary tract abnormalities.
• Real-world Use:
  Increasingly adopted in geriatric, renal, and palliative care populations where antibiotics are undesirable or contraindicated.

The Takeaway

Methenamine hippurate represents a safe, antibiotic-sparing, evidence-based option for preventing recurrent UTIs—particularly in an era of rising antibiotic resistance. Its success, however, depends on one simple but crucial detail: keeping the urine acidic.

With proper guidance, regular monitoring, and supportive dietary measures, methenamine can offer lasting relief and protection for those caught in the cycle of recurrent infections—restoring comfort, confidence, and control over bladder health.

Sample Order Protocol (for LTC / Hospice Settings)

Indication: Recurrent urinary tract infections (≥2 in 6 months or ≥3 in 12 months)
Medication: Methenamine Hippurate 1 g PO BID with meals (for 3-12 months, depending on prescriber discretion and patient status)
Adjunct: Ascorbic Acid 500 mg PO BID

Monitoring:

• Urine pH weekly × 4 weeks, then monthly
• Notify NP/MD if pH > 6.5 or symptoms of infection
• Hold methenamine during active UTI or antibiotic therapy; resume after completion

References

1. Harding C, Chadwick T, Homer T, Lecouturier J, Mossop H, Carnell S, King W, Abouhajar A, Vale L, Watson G, Forbes R, Currer S, Pickard R, Eardley I, Pearce I, Thiruchelvam N, Guerrero K, Walton K, Hussain Z, Lazarowicz H, Ali A. Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT. Health Technol Assess. 2022 May;26(23):1-172. 

• Harding C, Mossop H, Homer T, Chadwick T, King W, Carnell S, Lecouturier J, Abouhajar A, Vale L, Watson G, Forbes R, Currer S, Pickard R, Eardley I, Pearce I, Thiruchelvam N, Guerrero K, Walton K, Hussain Z, Lazarowicz H, Ali A. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. BMJ. 2022 Mar 9;376.

1. Lee B, Bhuta T, Craig J, Simpson J. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev. 2002;(1):CD003265. doi: 10.1002/14651858.CD003265. Update in: Cochrane Database Syst Rev. 2007 Oct 17;(4).
2. Rau M, Santelli A, Martí S, Díaz MI, Sabé N, Fiol M, Riera L, Etcheverry B, Codina S, Coloma A, Carreras-Salinas A, Ardanuy C, Cruzado JM, Melilli E. Randomized clinical trial of non-antibiotic prophylaxis with d-Mannose plus Proanthocyanidins vs. Proanthocyanidins alone for urinary tract infections and asymptomatic bacteriuria in de novo kidney transplant recipients: The Manotras study. Nefrologia (Engl Ed). 2024 May-Jun;44(3):408-416.
3. Fasugba O, Mitchell BG, McInnes E, Koerner J, Cheng AC, Cheng H, Middleton S. Increased fluid intake for the prevention of urinary tract infection in adults and children in all settings: a systematic review. J Hosp Infect. 2020 Jan;104(1):68-77.
4. AUA Recurrent UTI Guidelines, 2025 Update.
5. Dason S, Dason JT and Kapoor A: Guidelines for the diagnosis and management of recurrent urinary tract infection in women. Can Urol Assoc J 2011; 5: 316